Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

NCT07130695 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Olutasidenib Investigational Agent Administration

Sponsor

Virginia Commonwealth University

Collaborators

[object Object]